🔗 Share this article

While America undertakes historic revisions to its vaccine schedules, an unexpected name appears unexpectedly: Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccines throughout the pandemic and has concentrated on possible deaths following Covid immunization in her short time at the FDA.

Scheduled Overhauls to Pediatric Vaccine Program

Health officials were set to unveil radical changes to the pediatric vaccination calendar recently, aligning the US with the Danish national calendar, sources say – a significant shift that would put the US out of step with a large portion of the global community with insufficient data for public health gain. The announcement has been postponed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to present at the meeting. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth appointee to run the division this year.

A New Direction at the FDA

Høeg's temporary position might represent a tighter collaboration between the drug and biologics centers as Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Høeg has frequently advocated for discontinuing certain pediatric immunization guidelines in the US in order to be more similar to Denmark's approach, a country with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

To date public appearances, she has continued to focus on vaccination policy – usually the purview of Dr. Prasad, director of the FDA’s vaccine center – rather than medication approval.

Doubts Over Expertise

Høeg has no obvious experience in pharmaceutical research, oversight or administrative roles, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the CDER, said Dr. Jonathan Howard. “She has not conducted a scientific study. She is not versed in managing a large organization. She lacks background in drug approvals.”

Former heads of the center would “understand regulatory frameworks and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that previous people who ran the center have had.”

The drug center has an vast portfolio at the FDA, she emphasized.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division authorizes numerous off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and other areas, and each of these must be managed,” Woodcock explained. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant management component to the position, which manages in excess of 5,000 staff members. “It’s a enormous administrative position, if you do it right,” Woodcock said.

Official Statement and Controversial Policies

Regarding concerns about Dr. Høeg's credentials and whether this selection signifies more teamwork among FDA leaders on immunizations, a representative responded that the “concerns are based on incorrect premises”.

“Her resume aligns with the duties of her role,” the spokesperson said, citing the period Høeg spent guiding the agency head on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial rapid drug-approval program that reportedly worried her preceding directors. “By what process are these drugs being selected for this fast-track system? Who is making the choices?” Dr. Howard said. “There is a lot of secrecy going on at the regulatory body right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards more relaxed regulations of most medications, aside from immunizations.”

Established History on Vaccines

With vaccines, Dr. Høeg has a more documented, if problematic, track record, Howard observe. She released a analysis using non-validated public submissions to determine the frequency of heart inflammation after COVID-19 vaccination. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Among her “desired changes” for the incoming federal leadership included altering rules for new vaccines and discontinuing “non-essential” vaccines, she remarked following the vote on a podcast. At the agency, Høeg has according to sources suggested barring adolescent males from obtaining COVID-19 vaccines.

“She’s an complete true believer who commences with her conclusions and tailors the evidence to accommodate the data in a highly deceptive, untruthful way,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|